Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-13-1536
Full Text
Open PDFAbstract
Available in full text
Date
September 13, 2013
Authors
Publisher
American Association for Cancer Research (AACR)